Review of P‐gp Inhibition Data in Recently Approved New Drug Applications: Utility of the Proposed [I1]/IC50 and [I2]/IC50 Criteria in the P‐gp Decision Tree
- 22 February 2013
- journal article
- review article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 53 (2) , 228-233
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Transporter-Mediated Drug–Drug InteractionsClinical Pharmacology & Therapeutics, 2011
- Interaction Potential of Etravirine with Drug Transporters Assessed In VitroAntimicrobial Agents and Chemotherapy, 2011
- The Utility of In Vitro Data in Making Accurate Predictions of Human P-Glycoprotein-Mediated Drug-Drug Interactions: A Case Study for AZD5672Drug Metabolism and Disposition, 2011
- Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitroJournal of Antimicrobial Chemotherapy, 2011
- Transporters in drug development: advancing on the Critical PathNature Reviews Drug Discovery, 2010
- Membrane transporters in drug developmentNature Reviews Drug Discovery, 2010
- Refining the In Vitro and In Vivo Critical Parameters for P-Glycoprotein, [I]/IC50 and [I2]/IC50, That Allow for the Exclusion of Drug Candidates from Clinical Digoxin Interaction StudiesMolecular Pharmaceutics, 2009
- Drug–Drug Interactions Mediated Through P-Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe DrugClinical Pharmacology & Therapeutics, 2008
- A regulatory viewpoint on transporter-based drug interactionsXenobiotica, 2008
- Prediction of Intestinal First-Pass Drug MetabolismCurrent Drug Metabolism, 2007